Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 754-765

  Derks, Michael ^a   Kawamura, Hitoshi ^b   Abt, Markus ^a   Meneses Lorente, Georgina ^c   Phelan, Mary ^c   Ishikawa, Tomohiro ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b JAPAN TOBACCO INC   (Japan)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

AUC; CETP; Dalcetrapib; Fasting; Fed; HDL C

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGGRESSION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVENING DOSAGE; FLATULENCE; FLUOROMETRY; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MORNING DOSAGE; MUSCLE CRAMP; MYALGIA; NORMAL HUMAN; PARESTHESIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHLEBITIS; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SUPRAVENTRICULAR PREMATURE BEAT; TOOTH PAIN; VITAL SIGN;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHOLESTEROL ESTER TRANSFER PROTEINS; CROSS-OVER STUDIES; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; SULFHYDRYL COMPOUNDS; TIME FACTORS; YOUNG ADULT;

EID: 79959451496     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.046     Document Type: Article

References (30)

1. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310. Treating to New Targets (TNT) Investigators.
2. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. Treating to New Targets (TNT) Investigators.
3. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.
4. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
5. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl):S11-S20.
6. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
7. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323:1234-1238.
8. Ordovas J.M., Cupples L.A., Corella D., et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham Study. Arterioscler Thromb Vasc Biol 2000, 20:1323-1329.
9. Brousseau M.E., O'Connor J.J., Ordovas J.M., et al. Cholesteryl ester transfer protein Taq1 B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency. Arterioscler Thromb Vasc Biol 2002, 22:1148-1154.
10. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004, 110:1418-1423.
11. Klerkx A.H., de Grooth G.J., Zwinderman A.H., et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004, 34:21-28.
12. Barter P.J., Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006, 47:492-499.
13. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
14. Kuivenhoven J.A., de Grooth G.J., Kawamura H., et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95:1085-1088.
15. Stein E.A., Stroes E.S., Steiner G., et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009, 104:82-91.
16. Stein E.A., Roth E.M., Rhyne J.M., et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010, 31:480-488.
17. Derks M., Fowler S., Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009, 25:891-902.
18. Derks M., Abt M., Parr G., et al. No clinically relevant drug-drug interactions when dalcetrapib is coadministered with atorvastatin. Expert Opin Investig Drugs 2010, 19:1135-1145.
19. Derks M., Abt M., Phelan M., et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010, 50:1188-1201.
20. Fleisher D., Li C., Zhou Y., Pao L.-H., Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin. Pharmacokinet 1999, 36:233-254.
21. Dale O., Salo M. The Helsinki Declaration, research guidelines and regulations: present and future editorial aspects. Acta Anaesthesiol Scand 1996, 40:771-772.
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis 1997, 48:231-234.
23. Kuhlmann O., Heinig K. Dalcetrapib pharmacokinetics and metabolism in the Cynomolgus monkey. Xenobiotica 2011, 41:430-436.
24. Kato H., Nakanishi T., Arai H., et al. Purification, microheterogeneity, and stability of human lipid transfer protein. J Biol Chem 1989, 264:4082-4087.
25. CETP- Activity (Cholesteryl Ester Transfer Protein Activity) Pacific Biomarkers Inc, Accessed May 23, 2011. http://www.pacbio.com/biomarker/assay_detail.php?id=16.
26. Gibaldi M., Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics 1982, Marcel Dekker, New York, NY.
27. Hourcade-Potelleret F. Preliminary population PK-PD of dalcetrapib: an agent targeting CETP to raise HDL-C and prevent cardiovascular morbidity and mortality Accessed June 9, 2010. http://www.page-meeting.org/?abstract=1807.
28. Krishna B., Bergman A.J., Jin B., et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008, 84:679-683.
29. Schwartz G.G., Olsson A.G., Ballantyne C.M., et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009, 158:896-901. dal-OUTCOMES Committees and Investigators.
30. Derks M., Abt M., Mwangi A., Meneses-Lorente G. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010, 66:775-783.